Insight
Millennial women are missing lifesaving cancer checks – how to close the cervical screening gap

As new European research shows millennials are more likely to miss cervical cancer screenings than any other generation, experts warn that failing to address major barriers – from fear to family and workplace pressures – could undermine global elimination targets.
Results from a survey of over 5,500 women aged 16-64 found that 31 per cent of eligible millennials have postponed or missed their cervical screening appointments, a figure that is 27 per cent higher than the average across all age groups.
The research, commissioned by Roche Diagnostics and conducted by GWI across six European countries, also found that, despite screening services being widely available free of charge or heavily subsidised in many countries, specific challenges make accessing routine cervical screening difficult for some.
Fears related to pain, embarrassment or stigma surrounding cervical screenings are well-documented as contributing to lower screening rates. But the research also reveals particular challenges millennials face in balancing careers, caregiving responsibilities, and relationships often result in appointments being missed or delayed at a higher rate compared to other age groups.
The ‘have it all’ generation?
“Millennials are often said to be the ‘have it all generation,’ juggling careers, caregiving, and societal expectations. Yet, they tend to put themselves last,” said Joanna Sickler, Vice-President, Health Policy and External Affairs at Roche Diagnostics.
“The research shows that millennials are disproportionately failing to prioritise cervical screening because of a mix of emotional, logistical, and societal pressures.”
Cervical cancer affects more than 600,000 women globally every year, yet it is preventable in almost all cases through vaccination, early detection, and treatment of precancers. Cervical screenings remain vital for detecting human papillomavirus (HPV), the cause of over 99 per cent of cervical cancers, but participation has declined in recent years.
In England, cervical screening rates have fallen to around 69 per cent for women aged 25–64 – well below the NHS England target of 80 per cent – with rates lower for younger women (66 per cent) than older women (74 per cent). According to NHS data, this means over five million women are not up to date with their routine check-up.
The high prevalence of millennials missing screening appointments is particularly concerning, given that they may be the age group that is most at risk. Between 1990 and 2019, cases of early-onset cancer among people under 50 increased by 79 per cent worldwide, and mortality by 28 per cent, making millennials the first generation at greater risk of developing tumours than their parents.
Research also indicates a rise in cases of cervical cancer among millennial women, despite the World Health Organization’s commitment to eliminating it as a public health problem by 2030. A study published in JAMA in 2022 revealed that the incidence of the disease has risen by an average of 2.5 per cent per year among women 30 to 34 years old since 2012.
Experts believe that the reduction in screening uptake among this age group could be contributing to the rise in cervical cancer rates.
A separate study, published in JAMA Network Open, found that of over 20,000 US women surveyed between 2005 and 2019, the percentage of those overdue for cervical cancer screening rose from 14 per cent in 2005 to 23 per cent in 2019.
Women aged 21–29 were significantly more likely to be overdue for screening than those between the ages of 30 and 65.
Fear remains the biggest barrier
According to Roche’s research, fear remains the biggest barrier to attending cervical screenings, with 30 per cent citing fear as the primary reason for missing or delaying their appointments, driven by anxiety about discomfort, pain, or the potential results. This was particularly common among younger generations.
In Spain, 43 per cent of respondents cited fear as a reason for delay, the highest across all surveyed markets. Across the wider survey, 36 per cent of those aged between 16 and 34 years old and 37 per cent of those without children were also significantly more likely to delay due to fear.
This appears to be compounded by a lack of awareness and open dialogue about cervical screening. Despite various public health initiatives to encourage uptake, nearly 50 per cent of respondents, including 43 per cent of millennials, admitted they had never spoken to anyone about cervical screening, with 10 per cent saying they would be more likely to attend if encouraged by family, friends, or colleagues.
“It’s important to create an environment where discussing cervical screening and women’s health topics is not only accepted but encouraged,” Sickler tells Femtech World.
“This can only happen if these topics become commonplace in homes, workplaces and communities.”
Work, family and societal pressures
But fear is not the only factor.
The survey also found that professional commitments and workplace demands are the second-largest barrier for all participants. High-income earners, or those in the top third of income ranges across markets, are 22 per cent more likely than average to delay appointments, and 27 per cent of this group cite workplace demands as the reason for postponement.
Caregiving responsibilities are also often prioritised over personal health, particularly for parents, with 27 per cent of parents surveyed reporting they had delayed or cancelled cervical screening appointments.
Among millennials who postponed their screenings, 12 per cent identified assistance with travel or childcare as a significant motivator, while 19 per cent said greater workplace flexibility and encouragement from employers would help them prioritise their appointments.
According to Sickler, although 66 per cent of managers agree on the importance of taking an active role in supporting employees to attend screenings, only 14 per cent offer flexibility, and just eight per cent have discussed the topic at work.
At the same time, evidence shows the burden of cervical cancer falls disproportionately on marginalised and underserved communities, with incidence rates of cervical cancer in the UK 65 per cent higher in the most deprived quintile of the population, and approximately 520 cervical cancer cases each year linked to deprivation.
Meeting women where they are
Professor Daniel Kelly OBE, Cardiff University, and co-chair of the HPV and Hep B Action Network at the European Cancer Organisation, says healthcare systems “must evolve to meet women where and how they live”. And more broadly, society and communities should “foster open dialogue” to “normalise cervical health as a shared responsibility”.
Sickler agrees that healthcare systems must adapt to better address some of the barriers facing millennial women through practical and cultural solutions – from strengthening awareness and support to streamlining booking systems and expanding access to alternative screening options like self-sampling.
“The latest findings highlight opportunities to improve screening participation through education, workplace flexibility and access to resources,” she says.
“Whilst millennials are the most likely to miss cervical screening appointments, our research also shows they are also the generation most likely to request alternative screening options (21 per cent) and a more convenient booking process (35 per cent).
“To meet these needs, health systems could expand alternative screening options such as self-collection, which offers privacy and convenience and helps overcome barriers like embarrassment, fear of discomfort, and cultural stigma.
Sickler adds: “Streamlining booking processes, strengthening patient education, and fostering open conversations to normalise cervical health are crucial steps in overcoming key barriers.”
NHS to roll out home HPV testing
In England, where the NHS has promised to eliminate cervical cancer by 2040, more women are expected to be offered home screening kits as part of the cervical screening programme outlined in the recently published 10 Year Plan.
From January 2026, HPV self-sampling kits will be offered to those who have rarely or never attended their cervical screening appointment to allow them to test at home. The programme is specifically aimed at groups consistently missing vital appointments, including younger women, ethnicities facing cultural hurdles, people with disabilities and the LGBT+ community.
The new policy was informed by research carried out by King’s College London in 2021, which provided HPV self-sampling kits to women and people with a cervix who were at least six months overdue for their cervical screening. The YouScreen trial found that offering self-sampling kits could boost the numbers screened in England by about 400,000 each year.
According to Dr Anita Lim, visiting senior research fellow at King’s and chief investigator of the trial, the findings demonstrated that self-sampling could reach people who find it difficult to attend traditional screening, including those from diverse and underserved populations.
“It’s hugely positive to see this now reflected in national policy, helping more people get protected from this highly preventable cancer,” said Lim.
While screening carried out by a clinician is still considered the “gold standard” for HPV testing, experts and leading charities such as Cancer Research UK and The Eve Appeal have welcomed the initiative, saying it will help remove barriers and make cervical screening more accessible. And anyone who tests positive for HPV through self-sampling will be encouraged to attend a clinician-taken follow-up screening test.
“The gold standard way to test for HPV is still a sample taken by a clinician, and this will be suitable for most people,” said Michelle Mitchell, Chief Executive of Cancer Research UK, when the plans were announced back in June.
“But beating cervical cancer means beating it for everyone, and this move helps to bring us closer to that goal.”
A ‘societal movement’ to beat cervical cancer
Improving access to self-screening is one solution, but as Sickler highlights, it’s not the whole solution.
Roche’s new campaign, ‘Cervical cancer: it only ends with all of us’, focuses on several different ways to encourage those eligible to overcome barriers and attend clinician-collected cervical screenings.
This includes promoting more emotional and practical support from loved ones, better education across communities, and open conversations around the topic.
“The campaign aims to improve attendance rates through a societal movement to encourage and empower eligible populations to attend their cervical screening appointments,” Sickler adds.
“Only by creating an inclusive environment where women’s health topics are discussed will we be able to increase attendance and prevent cervical cancer from continuing to claim lives.”
Insight
Women with birth trauma face 2.5x higher healthcare costs – study

Women with childbirth-related PTSD had healthcare costs 2.5 times higher than women without PTSD from six to 12 months after birth, a report found.
The analysis estimated that early prevention of traumatic births and childbirth-related post-traumatic stress disorder (PTSD) could save the NHS around £26m each year.
Women with PTSD were also less likely to have returned to work by 12 months after giving birth, suggesting potential longer-term employment and economic effects.
The report from City St George’s, University of London was launched at an All-Party Parliamentary Group (APPG) on Birth Trauma event on 10 September 2026.
Researchers calculated the potential NHS savings using the number of births reported in NHS hospitals in 2024-25 and the UK prevalence of childbirth-related PTSD.
Around one in 20 women in the UK develop PTSD following childbirth, while recent research has shown that the condition remains underdiagnosed.
The findings draw on research that tracked more than 2,000 women in England and Scotland from pregnancy to two years after birth. Researchers assessed mental health, use of health services and employment outcomes.
The research included assessments of childbirth-related PTSD and PTSD arising from other traumatic experiences. It also included a separate Birth Trauma Association survey examining women’s experiences of birth trauma.
Between six and 12 months after birth, healthcare and support service costs for women with childbirth-related PTSD were 2.5 times those of women without PTSD.
Women with low or moderate symptoms, including those reporting one or two PTSD symptoms, also had higher healthcare service costs than women without PTSD.
Just over half, 53 per cent, of women with PTSD had returned to work by 12 months after giving birth, compared with 68 per cent of women without symptoms.
Women with PTSD were more likely to be referred for mental health support, but more than half received no referral.
Those whose PTSD followed a traumatic birth also had slightly higher healthcare costs than women whose PTSD resulted from other traumatic experiences.
The researchers called for routine PTSD assessment and treatment during pregnancy and after childbirth, alongside greater access to specialist perinatal mental health services.
They also recommended training healthcare staff in perinatal trauma, trauma-informed care and identifying women at risk of PTSD.
The report said further research was needed to establish whether screening, treatments and trauma-informed care pathways are effective and evidence based.
The work follows the APPG’s 2024 Birth Trauma Inquiry, which highlighted the effects of birth trauma on women and families and called for evidence on its wider public health and societal costs.
The report focused primarily on healthcare use and did not attempt to calculate all costs associated with birth trauma and postnatal PTSD, including wider employment, family and societal effects.
Insight
UK reviews surrogacy firm over rejected insurance claims

The UK government is reviewing a surrogacy firm after complaints that medical insurance claims involving surrogates in Mexico were rejected.
The Department of Health and Social Care (DHSC) is considering whether UK-based provider My Surrogacy Journey should remain listed on gov.uk as one of four domestic surrogacy agencies available to intended parents.
The review follows allegations concerning its Mexican sister company, where surrogates are based.
Health minister Diana Johnson said: “The department is looking into the allegations about My Surrogacy Journey.
“As part of that assessment, the department will consider whether it is appropriate for that company to remain on the gov.uk list of agencies.”
Emails sent by My Surrogacy Journey chief executive Michael Johnson-Ellis and seen by the Guardian suggest multiple surrogate women in Mexico had their insurance claims rejected.
The emails also suggest 300 couples using the company were moved to a new insurance provider because of the increased risk of claims being rejected.
Commercial surrogacy is banned in the UK, where only altruistic arrangements are permitted.
My Surrogacy Journey operates a not-for-profit UK branch alongside for-profit sister companies in Mexico and the US. All three companies have the same owners and chief executives.
The reported insurance issues relate to surrogacy arrangements in Mexico.
One couple told the Guardian they paid tens of thousands of pounds to cover medical costs after their surrogate had a hysterectomy during childbirth and an insurance claim was refused.
The Guardian said it understood that at least five sets of parents said they had to cover medical costs after insurance claims were rejected.
In an email to the couple whose surrogate underwent a hysterectomy, Johnson-Ellis wrote: “We have already told you that the insurance companies have been declining some of the claims and we are actively working with the broker to get this issue resolved but you should also consider that they may not be paid out and there is nothing we are able to do to change this …
“We appreciate this is not an insignificant sum but this genuinely is out of our control.”
Johnson-Ellis also said the company had switched insurance providers, writing: “We’re also managing this for 300 other journeys, which is a complex position to be in.”
Lawyers acting for My Surrogacy Journey said the company did not comment on individual cases, but that existing insurance policies were in place and claims continued to be accepted and processed.
They said the company understood that a small number of claims had been rejected and was supporting people seeking to resolve those claims with an insurer.
Under the surrogacy arrangements, intended parents are understood to be contractually required to cover medical costs not paid by an insurer.
The couple said they had been recommended the company’s Mexico option. Its website advertises that intended parents using the route can have a baby in “under 18 months”.
They said they were told the UK route could take up to five years and that the US option was much more expensive.
Lawyers for My Surrogacy Journey said prospective parents are given information about typical timelines, costs, legal frameworks and practical considerations, and that the 18-month timeframe is indicative only.
The couple said their surrogate developed placenta accreta, a serious condition in which the placenta attaches to the wall of the uterus.
Emails from Johnson-Ellis acknowledged that the insurance provider investigated the birth after the surrogate experienced health complications.
The parents are considering legal action, while the Guardian said it understood at least four other couples were reviewing their options.
Phil Brickell, MP for Bolton West, raised concerns in parliament about a separate couple who had used My Surrogacy Journey.
He said: “Two of my constituents recently travelled to Mexico, where their children were born by surrogacy.
“Those births were facilitated by a company called My Surrogacy Journey, which is listed on gov.uk.
“While in Mexico, they had repeated traumatic experiences with the company relating to issues including insurance for their children, accusations of bullying towards staff and repeated efforts to silence any constructive criticism.
“I understand that other members of this house have received similar complaints.”
Brickell called for My Surrogacy Journey to be removed from gov.uk pending a review by the Human Fertilisation and Embryology Authority.
Lawyers acting for My Surrogacy Journey said the company was communicating with DHSC and was confident any issues could be resolved.
Insight
Research uncovers potential new target for breast cancer therapy

Targeting CD1d altered immune cells slowed tumour growth and improved immunotherapy responses in mouse models of breast cancer, researchers found.
The findings suggest blocking the molecule could make the environment around breast tumours more favourable to anti-cancer immune responses.
Further work is needed to understand how these immune changes occur and how the approach could be safely used in patients.
Researchers from King’s College London, the Francis Crick Institute and University College London investigated how immune cells inside breast tumours influence cancer growth.
They focused on myeloid cells, a group of immune cells found in large numbers within tumours that can either support an immune attack against cancer or contribute to tumour growth and immune evasion.
The team examined CD1d, a molecule found on the surface of myeloid and other immune and tissue cells that helps regulate immune responses.
When CD1d was genetically removed from cells in a mouse model of breast cancer, the mice were more resistant to tumour growth. Researchers also saw changes in myeloid cell populations, including increased activity among cells that can help attack cancer.
The team then blocked CD1d using an antibody and again observed changes in myeloid cells and slower tumour growth. Blocking CD1d also improved responses to immunotherapy in the mouse model.
Researchers used single-cell RNA sequencing, a technique that examines gene activity in individual cells, to investigate the immune changes in more detail.
They identified a population of myeloid cells called monocytes that expressed genes associated with inflammation, an important part of the immune response. These cells were particularly important in restricting tumour growth in the mouse models.
A similar pattern of gene activity was identified in data from human breast cancer tumours. Its presence in myeloid cells was associated with positive responses to immunotherapy in breast cancer patients.
However, the findings in people were based on gene expression data and did not test CD1d-targeting treatment in patients.
Professor Patricia Barral, professor of immunobiology at King’s College London and senior author of the study, said: “Many breast cancers do not respond well to current immunotherapies.
“Our findings reveal a previously unrecognised mechanism by which immune cells within tumours are regulated.
“While CD1d is best known for helping immune cells recognise lipid molecules, we found that it also plays a role in shaping the behaviour of myeloid cells within tumours.
“These findings suggest that targeting the immune cells that surround and support tumours could boost anti-cancer immunity and potentially improve treatment responses in the future.”
Researchers now plan to investigate how the immune changes occur and how they can be safely harnessed in patients.
They also want to examine whether targeting CD1d could enhance existing treatments and influence treatment responses in different cancer types.
The work was supported by UKRI BBSRC, Breast Cancer Now and the Cancer Research UK City of London Centre.
Entrepreneur2 weeks agoKOVE Medical raises €1.7 million to improve safety of foetal surgery
Pregnancy2 weeks agoUK study aims to transform maternity care for high-risk pregnancies
Fertility4 days agoParacetamol use may impact future fertility, studies suggest
Entrepreneur1 week agoLast chance to save on Women’s Health Week and Women’s Sport Summit: Early Bird pricing ends 11 September
Menopause1 week agoMenopause hormone treatment may ease brain fog, study suggests
Menopause6 days agoCancer drug could tackle osteoporosis menopause weight gain
Menopause2 weeks agoSpanish agency criticised for menopause guidelines based on male studies
Fertility2 weeks agoNHS IVF access review launched in Scotland











